Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: Carfilzomib vs Best Supportive Care in Relapsed/Refractory Multiple Myeloma
NCT01302392Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2010
- Primary completion
- Jul 2014
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 19
01
Overview
A Phase 3 trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Started Sep 2010; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01302392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302392.